 Aptinyx Inc. Nasdaq: APTX, a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the second quarter of 2020 and highlighted recent progress across the companys clinical-stage pipeline of novel NMDA receptor modulators. 